{"title":"LIFEPAK 20/20e defibrillator/monitor - component failures","public_updated_at":"2014-12-17T14:55:43Z","details":{"metadata":{"alert_type":"devices","issued_date":"2010-09-09","medical_specialism":["cardiology","dentistry"],"bulk_published":true,"document_type":"medical_safety_alert"},"change_history":[],"body":[{"content_type":"text/html","content":"<h2 id=\"device\">Device</h2>\n\n<p><img src=\"https://assets.digital.cabinet-office.gov.uk/media/5485ac3240f0b6024100028d/con093859.jpg\" alt=\"LIFEPAK 20/20e defibrillator/monitor, manufactured by Medtronic/Physio-Control (MDA/2010/070)\" /></p>\n\n<p>LIFEPAK 20/20e defibrillator/monitor.</p>\n\n<p>Manufactured by Medtronic/Physio-Control.</p>\n\n<p>Specific serial numbers are affected.</p>\n\n<p>This is an acute cardiac care device used in clinical and hospital settings. It has a dual power supply system and is designed to operate on AC (mains) power or DC (battery) power.</p>\n\n<p>Devices with specific serial numbers, manufactured from 31 July 2002 to 9 February 2009 inclusive, are affected. See the manufacturer’s <a rel=\"external\" href=\"http://www.mhra.gov.uk/home/ssLINK/CON084682\">Field Safety Notice</a> for a list of the relevant serial numbers.</p>\n\n<h2 id=\"problem\">Problem</h2>\n\n<p>Due to component failures, which affect AC (mains) and/or DC (battery) operating power, there is a risk that the defibrillator will not deliver therapy.</p>\n\n<p>The corrective action programme initiated by the manufacturer will take approximately two years to complete.</p>\n\n<h4 id=\"problem-1\">Problem 1</h4>\n\n<p>No DC (battery) operating power<br />\nCurrent leakage can prevent operation when using DC battery power.  Failure of DC power can result in an inability to deliver defibrillation therapy, if no AC power is available. The global failure rate is 0.9% to date.</p>\n\n<h4 id=\"problem-2\">Problem 2</h4>\n\n<p>No AC (mains) operating power<br />\nA component failure prevents AC power operation and prevents battery charging capability. Failure of AC power can result in an inability to deliver defibrillation therapy if DC power is depleted.  </p>\n\n<p>The global failure rate is 0.7% to date.</p>\n\n<h4 id=\"solution\">Solution</h4>\n\n<p>Affected devices may have problem 1, or problem 2, or both problems. The following phased corrective actions to replace the power supply board have been initiated:  </p>\n\n<ul>\n  <li>Phase 1 DC power – identifies devices at a higher risk that accounts for 92% of all DC power failures. The manufacturer expects to complete this phase in 9 to 12 months.  </li>\n  <li>Phase 2 AC power – identifies the remaining lower risk devices that will be updated upon completion of phase 1. The manufacturer expects phase 2 to take an additional 9-12 months to complete.  </li>\n</ul>\n\n<h2 id=\"action\">Action</h2>\n\n<ol>\n  <li>\n    <p>Assess the need for a back-up or alternative device whilst awaiting corrective action.</p>\n  </li>\n  <li>\n    <p>All users should ensure that:  </p>\n\n    <ul>\n      <li>they are aware of manufacturer’s <a rel=\"external\" href=\"http://www.mhra.gov.uk/home/ssLINK/CON084682\">Field Safety Notice</a>.  </li>\n      <li>the manufacturer’s recommended daily inspection and testing as per the operator’s checklist are performed.  </li>\n      <li>where possible, devices are connected to AC mains power and the DC battery kept continuously on charge.   </li>\n    </ul>\n  </li>\n  <li>\n    <p>The manufacturer has contacted all affected customers. However, if you wish to check if your device is affected, refer to the <a rel=\"external\" href=\"http://www.mhra.gov.uk/home/ssLINK/CON084682\">Field Safety Notice</a>.  </p>\n\n    <ul>\n      <li>Be aware of the two year timeline for completion of the corrective action. Assess the need for a back-up or alternative device during this period.  </li>\n      <li>If your device exhibits either or both problems, report the failure of the device to the manufacturer and to the MHRA. Arrange for repair of the device with the manufacturer.  </li>\n    </ul>\n  </li>\n</ol>\n\n<h2 id=\"distribution\">Distribution</h2>\n\n<p>This MDA has been distributed to:  </p>\n\n<ul>\n  <li>NHS trusts in England (Chief Executives)  </li>\n  <li>HSC trusts in Northern Ireland (Chief Executives)  </li>\n  <li>NHS boards in Scotland (Chief Executives)  </li>\n  <li>NHS boards and trusts in Wales (Chief Executives)  </li>\n  <li>Primary care trusts in England (Chief Executives)  </li>\n</ul>\n\n<h4 id=\"onward-distribution\">Onward distribution</h4>\n\n<p>Please bring this notice to the attention of all who need to know or be aware of it. This may include distribution by:</p>\n\n<p>Trusts to:<br />\nCAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:  </p>\n\n<ul>\n  <li>A&amp;E consultants  </li>\n  <li>A&amp;E departments  </li>\n  <li>A&amp;E directors  </li>\n  <li>A&amp;E nurses  </li>\n  <li>Adult intensive care units  </li>\n  <li>All clinical departments  </li>\n  <li>All staff  </li>\n  <li>All wards  </li>\n  <li>Anaesthesia, directors of  </li>\n  <li>Anaesthetic medical staff  </li>\n  <li>Anaesthetic nursing staff  </li>\n  <li>Anaesthetists  </li>\n  <li>Biomedical engineering staff  </li>\n  <li>Cardiac laboratory technicians  </li>\n  <li>Cardiac pacing technicians  </li>\n  <li>Cardiologists  </li>\n  <li>Cardiology departments  </li>\n  <li>Cardiology nurses  </li>\n  <li>Cardiology, directors of  </li>\n  <li>Cardiothoracic departments  </li>\n  <li>Cardiothoracic surgeons  </li>\n  <li>Cardiothoracic surgery directors  </li>\n  <li>Clinical governance leads  </li>\n  <li>Coronary care departments  </li>\n  <li>Coronary care nurses  </li>\n  <li>EBME departments  </li>\n  <li>Equipment stores  </li>\n  <li>Health and safety managers  </li>\n  <li>Intensive care units  </li>\n  <li>Intensive care, directors of  </li>\n  <li>Medical directors  </li>\n  <li>Medical libraries  </li>\n  <li>Midwifery staff  </li>\n  <li>MRI units, directors of  </li>\n  <li>Neonatal nurse specialists  </li>\n  <li>Neonatology departments  </li>\n  <li>Neonatology directors  </li>\n  <li>Outpatient theatre managers  </li>\n  <li>Paediatric intensive care units  </li>\n  <li>Patient transport managers  </li>\n  <li>Resuscitation officers and trainers  </li>\n  <li>Risk managers  </li>\n  <li>Theatre managers  </li>\n</ul>\n\n<p>Care Quality Commission (CQC) (England only) to:<br />\nThe MHRA considers this information to be important to:  </p>\n\n<ul>\n  <li>Care homes providing nursing care (adults)  </li>\n  <li>Clinics  </li>\n  <li>Hospitals in the independent sector  </li>\n  <li>Independent treatment centres  </li>\n  <li>Nursing agencies  </li>\n  <li>Private medical practitioners  </li>\n</ul>\n\n<p>Primary care trusts to:<br />\nCAS liaison officers for onward distribution to all relevant staff including:  </p>\n\n<ul>\n  <li>Community defibrillation officers  </li>\n  <li>Community hospitals  </li>\n  <li>Community nurses  </li>\n  <li>Equipment libraries and stores  </li>\n  <li>General practitioners  </li>\n  <li>Minor injury units  </li>\n  <li>NHS walk-in centres  </li>\n</ul>\n\n<h2 id=\"manufacturer-contact\">Manufacturer contact</h2>\n\n<div class=\"address\"><div class=\"adr org fn\"><p>\n\nLezlie Bridge  \n<br />Senior Regulatory Affairs Specialist - UK &amp; Ireland  \n<br />Medtronic Ltd  \n<br />Building 9, Croxley Green Business Park  \n<br />Watford  \n<br />WD18 8WW\n<br />\n<br />Tel: 01923 212 213  \n<br />Fax: 01923 202 550\n<br />\n</p></div></div>\n\n<p>Email: <a href=\"&#109;&#097;&#105;&#108;&#116;&#111;:&#108;&#101;&#122;&#108;&#105;&#101;&#046;&#106;&#046;&#098;&#114;&#105;&#100;&#103;&#101;&#064;&#109;&#101;&#100;&#116;&#114;&#111;&#110;&#105;&#099;&#046;&#099;&#111;&#109;\">&#108;&#101;&#122;&#108;&#105;&#101;&#046;&#106;&#046;&#098;&#114;&#105;&#100;&#103;&#101;&#064;&#109;&#101;&#100;&#116;&#114;&#111;&#110;&#105;&#099;&#046;&#099;&#111;&#109;</a></p>\n\n<h2 id=\"feedback\">Feedback</h2>\n\n<p>If you have any comments or feedback on this Medical Device Alert, please email us at: <a href=\"&#109;&#097;&#105;&#108;&#116;&#111;:&#100;&#116;&#115;&#064;&#109;&#104;&#114;&#097;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;\">&#100;&#116;&#115;&#064;&#109;&#104;&#114;&#097;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;</a> </p>\n\n<h2 id=\"england\">England</h2>\n\n<p>If you are in England, please send enquiries about this notice to the MHRA, quoting reference number MDA/2010/070 or 2010/006/003/081/021</p>\n\n<h4 id=\"technical-aspects\">Technical aspects</h4>\n\n<div class=\"address\"><div class=\"adr org fn\"><p>\n\nEnitan Taiwo or Nicole Small  \n<br />Medicines &amp; Healthcare products Regulatory Agency  \n<br />Market Towers 1 Nine Elms Lane  \n<br />London  \n<br />SW8 5NQ\n<br />\n<br />Tel: 020 7084 3122 / 3310  \n<br />Fax: 020 7084 3209\n<br />\n</p></div></div>\n\n<p>Email: <a href=\"&#109;&#097;&#105;&#108;&#116;&#111;:&#101;&#110;&#105;&#116;&#097;&#110;&#046;&#116;&#097;&#105;&#119;&#111;&#064;&#109;&#104;&#114;&#097;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;\">&#101;&#110;&#105;&#116;&#097;&#110;&#046;&#116;&#097;&#105;&#119;&#111;&#064;&#109;&#104;&#114;&#097;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;</a> or <a href=\"&#109;&#097;&#105;&#108;&#116;&#111;:&#110;&#105;&#099;&#111;&#108;&#101;&#046;&#115;&#109;&#097;&#108;&#108;&#064;&#109;&#104;&#114;&#097;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;\">&#110;&#105;&#099;&#111;&#108;&#101;&#046;&#115;&#109;&#097;&#108;&#108;&#064;&#109;&#104;&#114;&#097;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;</a></p>\n\n<h4 id=\"clinical-aspects\">Clinical aspects</h4>\n\n<div class=\"address\"><div class=\"adr org fn\"><p>\n\nJonathan Plumb  \n<br />Medicines &amp; Healthcare products Regulatory Agency  \n<br />Market Towers  \n<br />1 Nine Elms Lane  \n<br />London  \n<br />SW8 5NQ\n<br />\n<br />Tel: 020 7084 3128  \n<br />Fax: 020 7084 3111\n<br />\n</p></div></div>\n\n<p>Email: <a href=\"&#109;&#097;&#105;&#108;&#116;&#111;:&#106;&#111;&#110;&#097;&#116;&#104;&#097;&#110;&#046;&#112;&#108;&#117;&#109;&#098;&#064;&#109;&#104;&#114;&#097;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;\">&#106;&#111;&#110;&#097;&#116;&#104;&#097;&#110;&#046;&#112;&#108;&#117;&#109;&#098;&#064;&#109;&#104;&#114;&#097;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;</a></p>\n\n<h4 id=\"how-to-report-adverse-incidents\">How to report adverse incidents</h4>\n\n<p>Please report via our website: <a rel=\"external\" href=\"http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm\">Reporting adverse incidents involving medical devices</a>.</p>\n\n<p>Further information about CAS can be found on the <a rel=\"external\" href=\"https://www.cas.dh.gov.uk/Home.aspx\">Central Alerting System website</a> .</p>\n\n<h2 id=\"northern-ireland\">Northern Ireland</h2>\n\n<p>Alerts in Northern Ireland will continue to be distributed via the NI SABS system. </p>\n\n<p>Enquiries and adverse incident reports in Northern Ireland should be addressed to:  </p>\n\n<div class=\"address\"><div class=\"adr org fn\"><p>\n\nNorthern Ireland Adverse Incident Centre  \n<br />Health Estates Investment Group  \n<br />Room 17  \n<br />Annex 6  \n<br />Castle Buildings  \n<br />Stormont Estate  \n<br />Dundonald  \n<br />BT4 3SQ\n<br />\n<br />Tel: 02890 523 704  \n<br />Fax: 02890 523 900\n<br />\n</p></div></div>\n\n<p>Email: <a href=\"&#109;&#097;&#105;&#108;&#116;&#111;:&#078;&#073;&#065;&#073;&#067;&#064;&#100;&#104;&#115;&#115;&#112;&#115;&#110;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;\">&#078;&#073;&#065;&#073;&#067;&#064;&#100;&#104;&#115;&#115;&#112;&#115;&#110;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;</a></p>\n\n<p><a rel=\"external\" href=\"http://www.dhsspsni.gov.uk/index/hea/niaic.htm\">Northern Ireland Adverse Incident Centre (NIAIC)</a></p>\n\n<h4 id=\"how-to-report-adverse-incidents-in-northern-ireland\">How to report adverse incidents in Northern Ireland</h4>\n\n<p>Please report directly to NIAIC, further information can be found on the <a rel=\"external\" href=\"http://www.dhsspsni.gov.uk/niaic\">NIAIC website</a> .  </p>\n\n<p>Further information about SABS can be found on the <a rel=\"external\" href=\"http://sabs.dhsspsni.gov.uk/NISABS/default.aspx?CATID=3\">SABS website</a> .</p>\n\n<h2 id=\"scotland\">Scotland</h2>\n\n<p>Enquiries and adverse incident reports in Scotland should be addressed to:</p>\n\n<div class=\"address\"><div class=\"adr org fn\"><p>\n\nIncident Reporting and Investigation Centre  \n<br />Health Facilities Scotland  \n<br />NHS National Services Scotland  \n<br />Gyle Square  \n<br />1 South Gyle Crescent  \n<br />Edinburgh  \n<br />EH12 9EB\n<br />\n<br />Tel: 0131 275 7575  \n<br />Fax: 0131 314 0722\n<br />\n</p></div></div>\n\n<p>Email: <a href=\"&#109;&#097;&#105;&#108;&#116;&#111;:&#110;&#115;&#115;&#046;&#105;&#114;&#105;&#099;&#064;&#110;&#104;&#115;&#046;&#110;&#101;&#116;\">&#110;&#115;&#115;&#046;&#105;&#114;&#105;&#099;&#064;&#110;&#104;&#115;&#046;&#110;&#101;&#116;</a></p>\n\n<p><a rel=\"external\" href=\"http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric/\">Health Facilities Scotland - Incident Reporting and Investigation Centre</a> .</p>\n\n<h2 id=\"wales\">Wales</h2>\n\n<p>Enquiries in Wales should be addressed to:</p>\n\n<div class=\"address\"><div class=\"adr org fn\"><p>\n\nDr Sara Hayes  \n<br />Senior Medical Officer  \n<br />Medical Device Alerts  \n<br />Welsh Assembly Government  \n<br />Cathays Park  \n<br />Cardiff  \n<br />CF10 3NQ\n<br />\n<br />Tel: 029 2082 3922\n<br />\n</p></div></div>\n\n<p>Email: <a href=\"&#109;&#097;&#105;&#108;&#116;&#111;:&#072;&#097;&#122;&#045;&#065;&#105;&#099;&#064;&#119;&#097;&#108;&#101;&#115;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;\">&#072;&#097;&#122;&#045;&#065;&#105;&#099;&#064;&#119;&#097;&#108;&#101;&#115;&#046;&#103;&#115;&#105;&#046;&#103;&#111;&#118;&#046;&#117;&#107;</a></p>\n\n<h2 id=\"download-documents\">Download documents</h2>\n\n<p><a rel=\"external\" href=\"https://assets.digital.cabinet-office.gov.uk/media/5485ac3140f0b6024100028b/con093858.pdf\"> Medical Device Alert: LIFEPAK 20/20e defibrillator/monitor, manufactured by Medtronic/Physio-Control (MDA/2010/070) (374Kb)</a></p>\n"},{"content_type":"text/govspeak","content":"## Device\r\n\r\n![InlineAttachment:con093859.jpg]\r\n\r\nLIFEPAK 20/20e defibrillator/monitor.\r\n\r\nManufactured by Medtronic/Physio-Control.\r\n\r\nSpecific serial numbers are affected.\r\n\r\nThis is an acute cardiac care device used in clinical and hospital settings. It has a dual power supply system and is designed to operate on AC (mains) power or DC (battery) power.\r\n\r\nDevices with specific serial numbers, manufactured from 31 July 2002 to 9 February 2009 inclusive, are affected. See the manufacturer’s [Field Safety Notice](http://www.mhra.gov.uk/home/ssLINK/CON084682) for a list of the relevant serial numbers.\r\n\r\n## Problem\r\n\r\nDue to component failures, which affect AC (mains) and/or DC (battery) operating power, there is a risk that the defibrillator will not deliver therapy.\r\n\r\nThe corrective action programme initiated by the manufacturer will take approximately two years to complete.\r\n\r\n#### Problem 1\r\n\r\nNo DC (battery) operating power  \r\nCurrent leakage can prevent operation when using DC battery power.  Failure of DC power can result in an inability to deliver defibrillation therapy, if no AC power is available. The global failure rate is 0.9% to date.\r\n\r\n####Problem 2\r\n\r\nNo AC (mains) operating power  \r\nA component failure prevents AC power operation and prevents battery charging capability. Failure of AC power can result in an inability to deliver defibrillation therapy if DC power is depleted.  \r\n  \r\nThe global failure rate is 0.7% to date.\r\n\r\n####Solution  \r\n\r\nAffected devices may have problem 1, or problem 2, or both problems. The following phased corrective actions to replace the power supply board have been initiated:  \r\n  \r\n  * Phase 1 DC power – identifies devices at a higher risk that accounts for 92% of all DC power failures. The manufacturer expects to complete this phase in 9 to 12 months.  \r\n  * Phase 2 AC power – identifies the remaining lower risk devices that will be updated upon completion of phase 1. The manufacturer expects phase 2 to take an additional 9-12 months to complete.  \r\n  \r\n## Action\r\n\r\n1. Assess the need for a back-up or alternative device whilst awaiting corrective action.\r\n\r\n2. All users should ensure that:  \r\n  \r\n    * they are aware of manufacturer’s [Field Safety Notice](http://www.mhra.gov.uk/home/ssLINK/CON084682).  \r\n    * the manufacturer’s recommended daily inspection and testing as per the operator’s checklist are performed.  \r\n    * where possible, devices are connected to AC mains power and the DC battery kept continuously on charge.   \r\n  \r\n3. The manufacturer has contacted all affected customers. However, if you wish to check if your device is affected, refer to the [Field Safety Notice](http://www.mhra.gov.uk/home/ssLINK/CON084682).  \r\n  \r\n    * Be aware of the two year timeline for completion of the corrective action. Assess the need for a back-up or alternative device during this period.  \r\n    * If your device exhibits either or both problems, report the failure of the device to the manufacturer and to the MHRA. Arrange for repair of the device with the manufacturer.  \r\n  \r\n## Distribution\r\n\r\nThis MDA has been distributed to:  \r\n  \r\n  * NHS trusts in England (Chief Executives)  \r\n  * HSC trusts in Northern Ireland (Chief Executives)  \r\n  * NHS boards in Scotland (Chief Executives)  \r\n  * NHS boards and trusts in Wales (Chief Executives)  \r\n  * Primary care trusts in England (Chief Executives)  \r\n  \r\n#### Onward distribution  \r\n\r\nPlease bring this notice to the attention of all who need to know or be aware of it. This may include distribution by:\r\n\r\nTrusts to:  \r\nCAS and SABS (NI) liaison officers for onward distribution to all relevant staff including:  \r\n  \r\n  * A&E consultants  \r\n  * A&E departments  \r\n  * A&E directors  \r\n  * A&E nurses  \r\n  * Adult intensive care units  \r\n  * All clinical departments  \r\n  * All staff  \r\n  * All wards  \r\n  * Anaesthesia, directors of  \r\n  * Anaesthetic medical staff  \r\n  * Anaesthetic nursing staff  \r\n  * Anaesthetists  \r\n  * Biomedical engineering staff  \r\n  * Cardiac laboratory technicians  \r\n  * Cardiac pacing technicians  \r\n  * Cardiologists  \r\n  * Cardiology departments  \r\n  * Cardiology nurses  \r\n  * Cardiology, directors of  \r\n  * Cardiothoracic departments  \r\n  * Cardiothoracic surgeons  \r\n  * Cardiothoracic surgery directors  \r\n  * Clinical governance leads  \r\n  * Coronary care departments  \r\n  * Coronary care nurses  \r\n  * EBME departments  \r\n  * Equipment stores  \r\n  * Health and safety managers  \r\n  * Intensive care units  \r\n  * Intensive care, directors of  \r\n  * Medical directors  \r\n  * Medical libraries  \r\n  * Midwifery staff  \r\n  * MRI units, directors of  \r\n  * Neonatal nurse specialists  \r\n  * Neonatology departments  \r\n  * Neonatology directors  \r\n  * Outpatient theatre managers  \r\n  * Paediatric intensive care units  \r\n  * Patient transport managers  \r\n  * Resuscitation officers and trainers  \r\n  * Risk managers  \r\n  * Theatre managers  \r\n  \r\nCare Quality Commission (CQC) (England only) to:  \r\nThe MHRA considers this information to be important to:  \r\n  \r\n  * Care homes providing nursing care (adults)  \r\n  * Clinics  \r\n  * Hospitals in the independent sector  \r\n  * Independent treatment centres  \r\n  * Nursing agencies  \r\n  * Private medical practitioners  \r\n  \r\nPrimary care trusts to:  \r\nCAS liaison officers for onward distribution to all relevant staff including:  \r\n  \r\n  * Community defibrillation officers  \r\n  * Community hospitals  \r\n  * Community nurses  \r\n  * Equipment libraries and stores  \r\n  * General practitioners  \r\n  * Minor injury units  \r\n  * NHS walk-in centres  \r\n  \r\n## Manufacturer contact\r\n\r\n$A\r\nLezlie Bridge  \r\nSenior Regulatory Affairs Specialist - UK & Ireland  \r\nMedtronic Ltd  \r\nBuilding 9, Croxley Green Business Park  \r\nWatford  \r\nWD18 8WW\r\n\r\nTel: 01923 212 213  \r\nFax: 01923 202 550\r\n$A\r\n\r\nEmail: [lezlie.j.bridge@medtronic.com](mailto:lezlie.j.bridge@medtronic.com)\r\n\r\n## Feedback\r\n\r\nIf you have any comments or feedback on this Medical Device Alert, please email us at: [dts@mhra.gsi.gov.uk](mailto:dts@mhra.gsi.gov.uk) \r\n\r\n## England\r\n\r\nIf you are in England, please send enquiries about this notice to the MHRA, quoting reference number MDA/2010/070 or 2010/006/003/081/021\r\n\r\n#### Technical aspects  \r\n\r\n$A\r\nEnitan Taiwo or Nicole Small  \r\nMedicines & Healthcare products Regulatory Agency  \r\nMarket Towers 1 Nine Elms Lane  \r\nLondon  \r\nSW8 5NQ\r\n\r\nTel: 020 7084 3122 / 3310  \r\nFax: 020 7084 3209\r\n$A\r\n\r\nEmail: [enitan.taiwo@mhra.gsi.gov.uk](mailto:enitan.taiwo@mhra.gsi.gov.uk) or [nicole.small@mhra.gsi.gov.uk](mailto:nicole.small@mhra.gsi.gov.uk)\r\n\r\n#### Clinical aspects  \r\n\r\n$A\r\nJonathan Plumb  \r\nMedicines & Healthcare products Regulatory Agency  \r\nMarket Towers  \r\n1 Nine Elms Lane  \r\nLondon  \r\nSW8 5NQ\r\n\r\nTel: 020 7084 3128  \r\nFax: 020 7084 3111\r\n$A\r\n\r\nEmail: [jonathan.plumb@mhra.gsi.gov.uk](mailto:jonathan.plumb@mhra.gsi.gov.uk)\r\n\r\n#### How to report adverse incidents  \r\n\r\nPlease report via our website: [Reporting adverse incidents involving medical devices](http://www.mhra.gov.uk/Safetyinformation/Reportingsafetyproblems/Devices/index.htm).\r\n\r\nFurther information about CAS can be found on the [Central Alerting System website](https://www.cas.dh.gov.uk/Home.aspx) .\r\n\r\n## Northern Ireland\r\n\r\nAlerts in Northern Ireland will continue to be distributed via the NI SABS system. \r\n\r\nEnquiries and adverse incident reports in Northern Ireland should be addressed to:  \r\n  \r\n\r\n$A\r\nNorthern Ireland Adverse Incident Centre  \r\nHealth Estates Investment Group  \r\nRoom 17  \r\nAnnex 6  \r\nCastle Buildings  \r\nStormont Estate  \r\nDundonald  \r\nBT4 3SQ\r\n\r\nTel: 02890 523 704  \r\nFax: 02890 523 900\r\n$A\r\n\r\nEmail: [NIAIC@dhsspsni.gov.uk](mailto:NIAIC@dhsspsni.gov.uk)\r\n\r\n[Northern Ireland Adverse Incident Centre (NIAIC)](http://www.dhsspsni.gov.uk/index/hea/niaic.htm)\r\n\r\n#### How to report adverse incidents in Northern Ireland \r\n \r\nPlease report directly to NIAIC, further information can be found on the [NIAIC website](http://www.dhsspsni.gov.uk/niaic) .  \r\n\r\nFurther information about SABS can be found on the [SABS website](http://sabs.dhsspsni.gov.uk/NISABS/default.aspx?CATID=3) .\r\n\r\n## Scotland\r\n\r\nEnquiries and adverse incident reports in Scotland should be addressed to:\r\n\r\n\r\n$A\r\nIncident Reporting and Investigation Centre  \r\nHealth Facilities Scotland  \r\nNHS National Services Scotland  \r\nGyle Square  \r\n1 South Gyle Crescent  \r\nEdinburgh  \r\nEH12 9EB\r\n\r\nTel: 0131 275 7575  \r\nFax: 0131 314 0722\r\n$A\r\n\r\nEmail: [nss.iric@nhs.net](mailto:nss.iric@nhs.net)\r\n\r\n[Health Facilities Scotland - Incident Reporting and Investigation Centre](http://www.hfs.scot.nhs.uk/online-services/incident-reporting-and-investigation-centre-iric/) .\r\n\r\n## Wales\r\n\r\nEnquiries in Wales should be addressed to:\r\n\r\n\r\n$A\r\nDr Sara Hayes  \r\nSenior Medical Officer  \r\nMedical Device Alerts  \r\nWelsh Assembly Government  \r\nCathays Park  \r\nCardiff  \r\nCF10 3NQ\r\n\r\nTel: 029 2082 3922\r\n$A\r\n\r\nEmail: [Haz-Aic@wales.gsi.gov.uk](mailto:Haz-Aic@wales.gsi.gov.uk)\r\n\r\n## Download documents\r\n\r\n[InlineAttachment:con093858.pdf]\r\n"}],"max_cache_time":10,"temporary_update_type":false,"attachments":[{"content_id":"7d465a36-c0ee-4995-ac79-52749852356e","title":" Medical Device Alert: LIFEPAK 20/20e defibrillator/monitor, manufactured by Medtronic/Physio-Control (MDA/2010/070) (374Kb)","url":"https://assets.digital.cabinet-office.gov.uk/media/5485ac3140f0b6024100028b/con093858.pdf","updated_at":"2014-12-08T13:48:32Z","created_at":"2014-12-08T13:48:34Z","content_type":"application/pdf"},{"content_id":"9a045f93-d6ff-428d-a13b-1aabf29aefb9","title":"LIFEPAK 20/20e defibrillator/monitor, manufactured by Medtronic/Physio-Control (MDA/2010/070)","url":"https://assets.digital.cabinet-office.gov.uk/media/5485ac3240f0b6024100028d/con093859.jpg","updated_at":"2014-12-08T13:48:33Z","created_at":"2014-12-08T13:48:34Z","content_type":"application/jpg"}],"headers":[{"text":"Device","level":2,"id":"device"},{"text":"Problem","level":2,"id":"problem"},{"text":"Action","level":2,"id":"action"},{"text":"Distribution","level":2,"id":"distribution"},{"text":"Manufacturer contact","level":2,"id":"manufacturer-contact"},{"text":"Feedback","level":2,"id":"feedback"},{"text":"England","level":2,"id":"england"},{"text":"Northern Ireland","level":2,"id":"northern-ireland"},{"text":"Scotland","level":2,"id":"scotland"},{"text":"Wales","level":2,"id":"wales"},{"text":"Download documents","level":2,"id":"download-documents"}]},"routes":[{"path":"/drug-device-alerts/medical-device-alert-lifepak-20-20e-defibrillator-monitor-component-failures","type":"exact"}],"redirects":[],"publishing_app":"specialist-publisher","rendering_app":"government-frontend","need_ids":[],"phase":"live","analytics_identifier":null,"document_type":"medical_safety_alert","schema_name":"specialist_document","first_published_at":"2016-02-29T09:24:10Z","base_path":"/drug-device-alerts/medical-device-alert-lifepak-20-20e-defibrillator-monitor-component-failures","description":"(Medtronic/Physio-Control) component failures affect AC (mains) and/or DC (battery) operating power, which may lead to the defibrillator not able to deliver therapy. (MDA/2010/070)","content_id":"e63dad8c-d866-4c0c-b737-3600d6c72239","locale":"en","expanded_links":{"organisations":[{"analytics_identifier":"EA63","api_path":"/api/content/government/organisations/medicines-and-healthcare-products-regulatory-agency","base_path":"/government/organisations/medicines-and-healthcare-products-regulatory-agency","content_id":"240f72bd-9a4d-4f39-94d9-77235cadde8e","description":null,"document_type":"organisation","locale":"en","public_updated_at":"2015-06-29T14:33:29Z","schema_name":"placeholder","title":"Medicines and Healthcare products Regulatory Agency","withdrawn":false,"details":{"brand":"department-of-health","logo":{"formatted_title":"Medicines &amp; Healthcare products<br/>Regulatory Agency","crest":"single-identity"}},"links":{}}]},"format":"specialist_document","navigation_document_supertype":"other","user_journey_document_supertype":"thing","email_document_supertype":"other","government_document_supertype":"other","payload_version":0}